TY - JOUR T1 - Optimizing antiviral treatment for seasonal influenza in the United States: A Mathematical Modeling Analysis JF - medRxiv DO - 10.1101/2020.07.28.20163741 SP - 2020.07.28.20163741 AU - Matan Yechezkel AU - Martial L Ndeffo Mbah AU - Dan Yamin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/30/2020.07.28.20163741.abstract N2 - Seasonal influenza remains a major health burden in the United States. Despite recommendations of early antiviral treatment of high-risk patients, the effective treatment coverage remains very low. We developed an influenza transmission model that incorporates data on infectious viral load, social contact, and healthcare-seeking behavior, to evaluate the population-level impact of increasing antiviral treatment timeliness and coverage among high-risk patients in the US. We found that increasing the rate of early treatment among high-risk patients who received treatment more than 48 hours after symptoms onset, would substantially avert infections and influenza-induced hospitalizations. We found that treatment of the elderly has the highest impact on reducing hospitalizations, whereas treating high-risk individuals aged 5-19 years old has the highest impact on transmission. The population-level impact of increased timeliness and coverage of treatment among high-risk patients was observed regardless of seasonal influenza vaccination coverage and the severity of the influenza season.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a research grant (grant No. 3409/19) from the Israel Science Foundation within the Israel Precision Medicine Partnership program (Dr. Yamin), and a faculty startup funding from Texas A&M College of Veterinary Medicine and Biomedical Sciences (Dr. Ndeffo-Mbah). The funders have no role in the design of the study, collection, analysis, and interpretation of data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB is applicable, as all data are publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMedical data are publicly available. ER -